EVAR后IA型内漏的处理:移植物取出与定制开窗腔内修复的比较
该单中心回顾性研究比较了EVAR后IA型内漏的两种处理策略:移植物取出(EXP)与定制开窗EVAR(F-EVAR)。
要点
- F-EVAR与EXP治疗EVAR后IA型内漏的30天死亡率和二次干预率相当。
- EXP仍是相关选择,因F-EVAR适用性有限且EXP结果可接受。
核心结论
- 在高容量中心,开放取出和开窗腔内修复治疗EVAR后IA型内漏均可获得满意结果。
- F-EVAR与早期并发症发生率降低相关。
- 开放取出仍是相关选择,因其结果可接受且F-EVAR适用性有限。
研究设计与样本
- 回顾性单中心分析,纳入2009年至2018年因EVAR后IA型内漏接受EXP或F-EVAR治疗的患者。
- 手术方式选择基于形态学因素(F-EVAR适用性)、瘤囊生长速率、急诊表现和/或患者症状。
主要发现
- 两组合并症和手术时年龄相当。
- 初始EVAR至再次干预的中位时间为60.4个月(34-85个月),组间无差异。
- 30天二次干预率(EXP: 11.5% vs F-EVAR: 9.1%)和死亡率(EXP: 3.8% vs F-EVAR: 3.3%)组间无差异。
关键数值与推荐
- 30天二次干预率:EXP组11.5%,F-EVAR组9.1%。
- 30天死亡率:EXP组3.8%,F-EVAR组3.3%。
- 1年生存率:EXP组84.0%,F-EVAR组86.6%。
临床怎么用
- 对于EVAR后IA型内漏,F-EVAR可作为优先考虑以降低早期主要不良事件。
- 开放取出仍是F-EVAR不适用或形态学不合适患者的重要选择。
- 治疗决策应基于形态学适用性、瘤囊生长速率、急诊表现和症状综合判断。
局限性
- 治疗选择非随机,存在选择偏倚。
- 原文未报告长期随访的详细结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Proximal type 1 endoleak after endovascular abdominal aortic aneurysmal repair (EVAR) remains challenging to solve with no existing consensus. This work aims to compare two different surgical strategies to remedy type IA endoleak: endograft explantation (EXP) and aortic reconstruction or relining by custom made fenestrated EVAR (F-EVAR). METHODS: A retrospective single centre analysis between 2009 and 2018 was conducted including patients treated for type IA endoleak after EVAR with either EXP or F-EVAR. The choice of surgical technique was based on morphological factors (F-EVAR eligibility), sac growth rate, emergency presentation and/or patient symptoms. Technical success, morbidity, secondary interventions, 30 day mortality, and long term survival according to Kaplan-Meier were determined for each group and compared. RESULTS: Fifty-nine patients (91% male, mean age 79 years) underwent either EXP (n = 26) or F-EVAR (n = 33) during the study period. The two groups were equivalent in terms of comorbidity and age at the time of procedure. The median time from initial EVAR was 60.4 months (34-85 months), with no difference between groups. The maximum aneurysm diameter was greater in the EXP group compared with the F-EVAR group, 86 mm (65-100) and 70 mm (60-80), respectively (p = .008). Thirty day secondary intervention (EXP: 11.5% vs. F-EVAR: 9.1%) and mortality (EXP: 3.8% vs. F-EVAR: 3.3%) rates did not differ between groups, while major adverse events at 30 days, defined by the current SVS guidelines, were lower in the F-EVAR group (2.4% vs. 13.6%; p = .016). One year survival rates were similar between the groups (EXP: 84.0% vs. F-EVAR: 86.6%). CONCLUSION: Open explantation and endovascular management with a fenestrated device for type IA endoleak after EVAR can be achieved in high volume centres with satisfactory results. F-EVAR is associated with decreased early morbidity. Open explantation is a relevant option because of acceptable outcomes and the limited applicability of F-EVAR.
引用
- Doumenc B, Mesnard T, Patterson BO, et al. Management of Type IA Endoleak After EVAR by Explantation or Custom Made Fenestrated Endovascular Aortic Aneurysm Repair. Eur J Vasc Endovasc Surg. 2021. PMID: 33414067. doi:10.1016/j.ejvs.2020.10.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。